Composition for improving muscle function, and preventing or ameliorating muscle diseases, comprising lactiplantibacillus plantarum MTY001

Lactiplantibacillus plantarum MTY001 addresses sarcopenia by promoting muscle differentiation and synthesis, offering a potential cure for muscle weakness and atrophy, enhancing muscle function and strength.

WO2026235327A1PCT designated stage Publication Date: 2026-11-12FERMENTEC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2026/005792
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-04-30
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

There is currently no effective cure for sarcopenia, a disease characterized by muscle loss and weakness, which affects the elderly and is associated with increased risk of metabolic syndrome, osteoporosis, fractures, and a fivefold increase in mortality, primarily due to the slowdown in muscle protein synthesis with aging.

Method used

The use of Lactiplantibacillus plantarum MTY001, a strain isolated for its ability to promote muscle differentiation and inhibit degradation, is incorporated into pharmaceutical, food, and feed compositions to prevent or treat muscle weakness, loss, and atrophy, enhancing muscle function.

Benefits of technology

Lactiplantibacillus plantarum MTY001 inhibits muscle breakdown, promotes synthesis, and improves muscle strength, effectively addressing muscle weakness and atrophy, and enhancing muscle function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2026005792_12112026_PF_FP_ABST
    Figure KR2026005792_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a composition comprising Lactiplantibacillus plantarum MTY001. The composition comprising Lactiplantibacillus plantarum MTY001 has the effects of improving muscle strength and enhancing muscle function and thus can be used as a composition for preventing or ameliorating muscle diseases or as a composition for enhancing muscle function.
Need to check novelty before this filing date? Find Prior Art

Description

Composition for improving muscle function, preventing or improving muscle diseases comprising Lactipirantibacterial Bacillus plantarum MTY001

[0001] The present invention relates to the use of Lactiplantibacillus plantarum MTY001 for the prevention, improvement, or treatment of muscle weakness, muscle loss, or muscle atrophy; and for the enhancement of muscle function.

[0002] Muscle accounts for approximately 40–50% of a person's body weight. Around the age of 50, the rate of muscle protein synthesis within muscle cells slows down compared to the rate of breakdown, causing muscles to begin degenerating rapidly and making individuals susceptible to muscle loss diseases. Sarcopenia, a disease characterized by a gradual decline in muscle mass and strength, primarily manifests as muscle loss and weakness. The significant reduction in physical activity not only impairs mental health but also lowers life satisfaction; furthermore, it can lead to easy injuries even during simple daily activities, potentially resulting in serious complications. While sarcopenia primarily affects the elderly, it is now occurring across all generations. Currently in Korea, one in six people is aged 65 or older, and the number of sarcopenia patients is on the rise due to the aging population. Recently, muscle loss in the elderly has been recognized as a disease rather than natural aging, and it is already being managed with a disease code assigned in the United States (2016), the WHO (2017), and Japan (2018), and a disease code was also assigned in Korea in 2021. It is known that in the presence of sarcopenia, the risk of death increases fivefold due to metabolic syndrome, including obesity, diabetes, and heart disease, as well as osteoporosis and fractures. Although a disease code has been assigned for sarcopenia, there is currently no cure available.

[0003] Accordingly, while researching the prevention, improvement, or treatment of muscle strength loss, muscle loss, or muscle atrophy, the inventors isolated Lactiplantibacillus plantarum MTY001, which promotes muscle differentiation and formation. Furthermore, by confirming that the isolated strain inhibits muscle degradation while simultaneously promoting muscle synthesis, the present invention was completed.

[0004] Accordingly, the object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of diseases caused by muscle weakness, muscle loss, or muscle atrophy, comprising the strain Lactiplantibacillus plantarum MTY001 (accession number: KCTC15788BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.

[0005] Another object of the present invention is to provide a composition for preventing or improving muscle weakness, muscle loss, or muscle atrophy comprising the strain Lactiplantibacillus plantarum MTY001 (accession number: KCTC15788BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.

[0006] Another objective of the present invention is to provide a composition for muscle enhancement and strength improvement comprising the strain Lactiplantibacillus plantarum MTY001 (accession number: KCTC15788BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.

[0007] Another objective of the present invention is to provide a method for preventing or treating a disease caused by muscle weakness, muscle loss, or muscle atrophy, comprising the step of administering the strain Lactiplantibacillus plantarum MTY001 (accession number: KCTC15788BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof to an individual in need thereof.

[0008] Another object of the present invention is to provide a use of the Lactiplantibacillus plantarum MTY001 (accession number: KCTC15788BP) strain, its culture medium, its concentrate, its lysate, its dried form, or a combination thereof, for the manufacture of a drug for the prevention or treatment of diseases caused by muscle loss, muscle atrophy, or muscle weakness.

[0009] To achieve the above objective, the present invention provides a pharmaceutical composition for the prevention or treatment of diseases caused by muscle weakness, muscle loss, or muscle atrophy, comprising the strain Lactiplantibacillus plantarum MTY001 (accession number: KCTC15788BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.

[0010] In addition, the present invention provides a food composition for preventing or improving muscle strength loss, muscle loss, or muscle atrophy comprising the strain Lactiplantibacillus plantarum MTY001 (accession number: KCTC15788BP), the culture medium thereof, the concentrate thereof, the mash thereof, the dried product thereof, or a combination thereof.

[0011] In addition, the present invention provides a health functional food composition for the prevention or improvement of muscle strength loss, muscle loss, or muscle atrophy comprising the strain Lactiplantibacillus plantarum MTY001 (accession number: KCTC15788BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.

[0012] In addition, the present invention provides a feed composition for preventing or improving muscle strength loss, muscle loss, or muscle atrophy comprising the strain Lactiplantibacillus plantarum MTY001 (accession number: KCTC15788BP), the culture medium thereof, the concentrate thereof, the crushed material thereof, the dried material thereof, or a combination thereof.

[0013] In addition, the present invention provides a composition for muscle enhancement comprising the Lactiplantibacillus plantarum MTY001 strain (accession number: KCTC15788BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.

[0014] In addition, the present invention provides a composition for strengthening muscle strength comprising the Lactiplantibacillus plantarum MTY001 strain (accession number: KCTC15788BP), the culture medium thereof, the concentrate thereof, the pulverized product thereof, the dried product thereof, or a combination thereof.

[0015] In addition, the present invention provides a method for preventing or treating a disease caused by muscle weakness, muscle loss, or muscle atrophy, comprising the step of administering the strain Lactiplantibacillus plantarum MTY001 (accession number: KCTC15788BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof to an individual in need thereof.

[0016] In addition, the present invention provides the use of the Lactiplantibacillus plantarum MTY001 (accession number: KCTC15788BP) strain, its culture medium, its concentrate, its lysate, its dried form, or a combination thereof for the manufacture of a drug for the prevention or treatment of diseases caused by muscle loss, muscle atrophy, or muscle weakness.

[0017] The Lactiplantibacillus plantarum MTY001 strain of the present invention has the effect of preventing muscle loss, muscle atrophy, or muscle weakness and enhancing muscle function. The Lactiplantibacillus plantarum MTY001 strain of the present invention can be utilized in various ways in the field of treating muscle loss, muscle atrophy, or muscle weakness; and in the field of enhancing muscle function.

[0018] Figure 1 shows the results of analyzing the phylogenetic tree (left) and ANI (right) of Lactobacillus plantarum MTY001 (DS1929).

[0019] Figure 2 shows the results of analyzing the YY1-promoter activity inhibitory function (a) and the effect on cell viability (b) of Lactobacillus plantarum MTY001 culture medium using the HTS (High-throughput screening); PHF20-pYY1-Gluc assay to evaluate muscle differentiation in C2C12 myoblasts.

[0020] Figure 3 shows the results of analyzing protein expression of biomarkers for muscle degradation (Atrogin-1, MuRF-1), muscle differentiation (MyoD), and muscle synthesis (S6K1, 4EBP1 phosphorylation) after treating a dexamethasone-induced muscle atrophy C2C12-cell model with a culture of Lactobacillus plantarum MTY001 for 24 hours. Figure 3a shows the results of Atrogin-1 expression analysis, Figure 3b shows the results of MyoD and MuRF-1 expression analysis, and Figure 3c shows the results of P-S6K1, S6K1, and P-4EBP1 expression analysis.

[0021] Figure 4 shows the results of analyzing mRNA expression of muscle degradation (Atrogin-1, MuRF-1) biomarkers (a) and muscle differentiation (MyoD, MyoG, MYH7) biomarkers (b) after treating a dexamethasone-induced muscle atrophy C2C12-cell model with a culture of Lactibacillus plantarum MTY001 for 24 hours.

[0022] Figure 5 shows the results of analyzing the myotube formation-promoting function of Lactibacillus plantarum MTY001 lactic acid bacteria culture medium in a dexamethasone-induced muscular atrophy C2C12-cell model through immunofluorescence staining of MyHC (Myosin heavy chain), a myotube biomarker.

[0023] Figure 6 shows the results of body weight change (a) and grip strength measurement (b) before and after administration of Lactibacillus plantarum MTY001 lactic acid bacteria culture solution to aged mice.

[0024] Figure 7 shows the test schedule (a) for evaluating muscle efficacy of administering Lactibacillus plantarum MTY001 probiotics (live bacteria) in a dexamethasone-induced muscle atrophy mouse model, and the results of measuring body weight (b) and grip strength (c) during the administration period.

[0025] Figure 8 shows the results of measuring total muscle mass (a) and right hind leg muscle mass (b), respectively, after the administration of Lactibacillus plantarum MTY001 lactic acid bacteria culture or lactic acid bacteria (live bacteria) to aged mice or dexamethasone-induced muscular atrophy mice.

[0026] Figure 9 shows the results of Western blotting (a) and a graph (b) of protein expression of muscle degradation (Atrogin-1) and muscle synthesis biomarkers (AKT, S6K1, and 4EBP1 phosphorylation) in the right hind leg calf muscle of aged mice administered Lactibacillus plantarum MTY001 lactic acid bacteria culture.

[0027] Figure 10 shows the results of analyzing mRNA expression of biomarkers for muscle degradation (MuRF-1), muscle differentiation (Myh 7, myogenin), and muscle synthesis (S6K1) in the anterior tibial muscle of the right hind leg of dexamethasone-induced muscular atrophy mice administered Lactibacillus plantarum MTY001 lactic acid bacteria (live bacteria).

[0028] The present invention will be described in detail below.

[0029] According to an embodiment of the present invention, the present invention provides a composition for preventing or improving muscle weakness, muscle loss, or muscle atrophy comprising the strain Lactiplantibacillus plantarum MTY001 (accession number: KCTC15788BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof. The composition for preventing or improving muscle weakness, muscle loss, or muscle atrophy may be a food composition, a health functional food composition, or a feed composition.

[0030] The inventors selected strains with activity promoting muscle differentiation and formation from a lactic acid bacteria culture library using a muscle differentiation evaluation HTS system, in the same manner as Example 1 described below. The selected strain, Lactiplantibacillus plantarum MTY001, was deposited with the Biological Resource Center (Jeongeup-si, Jeollabuk-do, Korea) on August 14, 2024, in accordance with the Treaty of Budapest, and was assigned accession number KCTC15788BP.

[0031] Experiments have confirmed that the selected Lactiplantibacillus plantarum MTY001 not only has no cytotoxicity but also inhibits muscle breakdown, promotes muscle synthesis, and improves muscle strength. Therefore, the Lactiplantibacillus plantarum MTY001 of the present invention can be utilized in various fields, including the treatment of muscle weakness diseases; fields related to increasing muscle strength; the treatment of muscle loss diseases; fields related to increasing muscle; and fields related to strengthening muscle function.

[0032] In a specific embodiment of the present invention, the strain preferably has one or more activities selected from the group consisting of promoting differentiation of muscle cells, inhibiting death of muscle cells, improving muscle strength, improving exercise performance, and increasing mineral content in the body, but the scope of the present invention is not limited thereto.

[0033] In the present invention, the culture medium refers to a medium containing by-products generated through the intake of nutrients and metabolism of a strain and the strain itself, obtained by culturing the strain in a medium; specifically, it may refer to a culture medium or culture product of the strain. Furthermore, a concentrated or diluted solution of the culture medium, a dried or freeze-dried product obtained by drying the culture medium, a modified or purified product of the culture medium, a crushed product obtained by crushing the culture medium, or a mixture thereof may also be included as an active ingredient in the composition of the present invention.

[0034] In a specific embodiment of the present invention, the strain may be included in the form of a live cell, a dead cell, or a combination thereof.

[0035] In the present invention, the cell refers to the strain of the present invention itself and includes the strain itself or a strain isolated from a culture medium by culturing said strain, and may be a live cell or a dead cell. The cell may be obtained by centrifuging the culture medium and taking the portion that settles to the bottom layer, or by letting it sit for a certain period of time and removing the liquid from the top, as it sinks to the bottom layer of the culture medium due to gravity.

[0036] In a specific embodiment of the present invention, the prevention or improvement of muscle strength reduction, muscle loss, or muscle atrophy may be muscle strengthening, muscle strength improvement, muscle enhancement, promotion of muscle differentiation, or muscle regeneration.

[0037] In the present invention, muscle differentiation refers to the process in which mononuclear myoblasts form multinuclear myotubes through fusion, and refers to the induction of such a process. Cells in the differentiation stage forming myotubes are identified through the expression of markers such as Pax7, MyoD, and MyoG. By promoting the differentiation of myoblasts, the number of muscle cells increases, which can ultimately lead to an increase in muscle mass in the individual.

[0038] In the present invention, muscle regeneration refers to the ability of a damaged muscle to recover to a normal state. The muscle regeneration may be an effect resulting from the promotion of muscle cell differentiation, which increases the absolute amount of muscle cells, or from an increase in the diameter of individual muscle canals.

[0039] Foods according to the present invention include, for example, various types of food, beverages, chewing gum, tea, vitamin complexes, functional foods, etc. In addition, foods include, but are not limited to, special nutritional foods (e.g., infant formula, baby food, etc.), processed meat products, fish products, tofu products, jelly products, noodles (e.g., ramen, noodles, etc.), bread products, health supplements, seasoning foods (e.g., soy sauce, soybean paste, red pepper paste, mixed sauce, etc.), sauces, confectionery products (e.g., snacks), candies, chocolates, chewing gum, ice cream, dairy products (e.g., fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various types of kimchi, pickled vegetables, etc.), beverages (e.g., fruit beverages, vegetable beverages, soy milk, fermented beverages, etc.), natural seasonings (e.g., ramen soup, etc.), and food additives. The above foods, beverages, or food additives may be manufactured by conventional manufacturing methods.

[0040] In the present invention, a health functional food refers to a group of foods to which added value has been imparted by utilizing physical, biochemical, or biotechnological methods to enable the function of the food to act or manifest for a specific purpose, or to a food processed by designing it to sufficiently express in the body the in vivo regulatory functions regarding the regulation of biological defense rhythms, disease prevention, and recovery possessed by the food composition. For the purposes of the present invention, the health functional food refers to one intended to promote muscle strength enhancement, muscle augmentation, muscle differentiation, or muscle regeneration activity.

[0041] When the composition of the present invention is used as an additive to food or health functional food, the composition may be added as is or used together with other ingredients, and may be used appropriately according to conventional methods. The amount of the active ingredient can be appropriately determined according to the purpose of use. Generally, when manufacturing food or beverages, the composition of the present invention may be added to the raw material in an amount preferably 50 parts by weight or less, more preferably 25 parts by weight or less. However, in the case of long-term consumption for the purpose of health control and hygiene, the above amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount greater than the above range.

[0042] The food or health functional food composition of the present invention may contain a food-grade carrier, or various conventional flavoring agents or natural carbohydrates as additional ingredients. Examples of the above-mentioned natural carbohydrates include monosaccharides, e.g., glucose, fructose, etc.; disaccharides, e.g., maltose, sucrose, etc.; polysaccharides, e.g., dextrin, cyclodextrin, etc., and conventional sugars, and sugar alcohols such as xylitol, sorbitol, erythritol, etc. The above-mentioned flavoring agents may advantageously include natural flavoring agents (taumatin), stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.), and synthetic flavoring agents (saccharin, aspartame, etc.).

[0043] In the present invention, the term "feed" refers to any natural or artificial meal, single-meal food, etc., consumed by an animal, or the components of said single-meal food. The feed composition according to the present invention can be prepared in various forms of feed known in the art, and preferably may include concentrated feed, roughage, and / or special feed, but is not limited thereto.

[0044] The feed composition of the present invention may be a feed additive composition. The feed additive composition includes a substance added to the feed for the purpose of various effects, such as alleviating disease symptoms in animals, supplementing nutrients and preventing weight loss, improving the digestibility and utilization of fiber in the feed, improving milk quality, preventing reproductive disorders and improving conception rates, and preventing high-temperature stress during the summer.

[0045] The feed additive composition of the present invention corresponds to an auxiliary feed under the Feed Management Act and may additionally include mineral preparations such as sodium bicarbonate, bentonite, magnesium oxide, and complex minerals; mineral preparations that are trace minerals such as zinc, copper, cobalt, and selenium; vitamin preparations such as carotene, vitamins A, E, nicotinic acid, and vitamin B complex; protected amino acid preparations such as methionine and lysine; protected fatty acid preparations such as calcium salts of fatty acids; probiotics (lactic acid bacteria preparations); probiotics such as yeast cultures and mold fermentation products; yeast preparations, etc.

[0046] Among the above feeds, concentrated feeds include, but are not limited to, seed grains such as wheat, oats, and corn; bran, which is a byproduct obtained by refining grains and includes rice bran, wheat bran, and barley bran; oilseed meal, which is a byproduct obtained by extracting oil from soybeans, rapeseed, sesame, flaxseed, and coconut; residues such as residual starch, which is the main component of starch residue remaining after removing starch from sweet potatoes, potatoes, etc.; fish meal, fish residue; fish soluble, which is a concentrated fresh liquid obtained from fish; meat meal; blood meal; feather meal; skim milk powder; dried whey, which is the residue obtained when making cheese from milk or casein from skim milk; yeast, Chlorella, and seaweed.

[0047] Among the above feeds, roughage includes raw grass feeds such as wild grass, pasture grass, and green cuts; root vegetables such as feed turnips, feed beets, and a type of turnip called lutea bearger; silage, which is a storage feed made by filling a silo with raw grass, green cut crops, and grains and fermenting them with lactic acid; hay made by cutting and drying wild grass and pasture grass; straw of livestock breeding crops; and leaves of legumes, but is not limited thereto. Special feeds include mineral feeds such as oyster shells and rock salt; urea feeds such as urea or its derivatives such as diuretic isobutane; feed additives and dietary supplements, which are substances added in trace amounts to compound feed to supplement components that are prone to being deficient when only natural feed ingredients are mixed, or to improve the shelf life of the feed, but are not limited thereto.

[0048] The feed additive composition according to the present invention can be prepared by adding one or more selected from the group consisting of ppGpp (Guanosine 5'-diphosphate 3'-diphosphate) deficient variant enteropathogenic E. coli (EPEC), lysed products thereof, and cultures of said strains, in an appropriate effective concentration range according to various feed manufacturing methods known in the art.

[0049] The feed additive according to the present invention can be applied without limitation to any individual intended for the prevention or improvement of muscle loss, muscle atrophy, or muscle weakness. For example, it can be applied to any individual, such as non-human animals like monkeys, dogs, cats, rabbits, guinea pigs, rats, mice, cattle, sheep, pigs, goats, etc., as well as birds and fish.

[0050]

[0051] According to another aspect of the present invention, the present invention provides a pharmaceutical composition for the prevention or treatment of diseases caused by muscle weakness, muscle loss, or muscle atrophy, comprising the strain Lactiplantibacillus plantarum MTY001 (accession number: KCTC15788BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.

[0052] In a specific embodiment of the present invention, the disease resulting from muscle weakness, muscle loss, or muscle atrophy is preferably one or more selected from the group consisting of sarcopenia, atony, muscular atrophy, muscular dystrophy, muscle degeneration, myotonic dystrophy, amyotrophic lateral sclerosis, myasthenia, and cachexia, and is applicable without limitation to any symptom, disease, or illness caused by muscle weakness, muscle loss, or muscle atrophy.

[0053] In the present invention, prevention refers to any act of suppressing or delaying the onset of a disease caused by muscle weakness, muscle loss, or muscle atrophy through the administration of a pharmaceutical composition according to the present invention. Furthermore, in the present invention, treatment refers to any act of improving or beneficially altering the symptoms of a disease caused by muscle weakness, muscle loss, or muscle atrophy through the administration of a pharmaceutical composition according to the present invention.

[0054] The pharmaceutical composition of the present invention may further include pharmaceutically acceptable additives, wherein the pharmaceutically acceptable additives may include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, malt syrup, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, Opadry, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, sucrose, etc. The pharmaceutically acceptable additive according to the present invention is preferably included in an amount of 0.1 to 90 parts by weight with respect to the composition, but is not limited thereto.

[0055] In addition, the pharmaceutical composition of the present invention may be administered in various oral or parenteral formulations during actual clinical administration. When formulating, it may be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants, and it is preferable to use suitable formulations known in the art. Carriers, excipients, and diluents that may be included in the composition include lactose, dextrose, sucrose, oligosaccharides, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, etc.

[0056] The above-mentioned solid dosage forms for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid dosage forms are prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Furthermore, the above-mentioned liquid dosage forms for oral administration include suspensions, liquid formulations, emulsions, syrups, etc., and may include various excipients, such as humectants, sweeteners, flavorings, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.

[0057] The above-mentioned preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspension solvents. Witepsol, Macrogol, Tween 61, cacao oil, laurin oil, glycerogelatin, etc. may be used as bases for suppositories. The above-mentioned parenteral administration may be performed using external application to the skin or by intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection.

[0058] The dosage of the pharmaceutical composition of the present invention varies depending on the patient's weight, age, gender, health condition, diet, time of administration, method of administration, excretion rate, and severity of the disease, and may be administered once a day or divided into several doses.

[0059] The pharmaceutical composition of the present invention can be administered to an individual via various routes.

[0060] The pharmaceutical composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers for the prevention or treatment of diseases caused by muscle weakness, muscle loss, or muscle atrophy.

[0061]

[0062] According to another aspect of the present invention, the present invention provides a composition for muscle enhancement; or for muscle strength enhancement comprising the strain Lactiplantibacillus plantarum MTY001 (accession number: KCTC15788BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.

[0063] In the present invention, the muscle enhancement and strength strengthening are preferably achieved through the promotion of muscle cell differentiation, inhibition of muscle cell death, improvement of muscle strength, improvement of exercise performance, or an increase in the body's mineral content.

[0064] In an embodiment of the present invention, the strain according to the present invention was orally administered to mice. As a result, the muscle and body mineral content of the mice were significantly increased, and the hip-shin muscle mass increased by up to 29% compared to before administration. In addition, in another embodiment of the present invention, when the strain according to the present invention was orally administered to aged mice, it was confirmed that grip strength and treadmill performance ability increased significantly. The above results indicate that the strain according to the present invention positively alters body composition and improves exercise ability, and thus can be utilized as a composition for muscle enhancement or strength strengthening.

[0065] The composition for muscle enhancement or muscle strength strengthening of the present invention can be manufactured in various forms such as food compositions, health functional food compositions, and food additive compositions, and can be used as an adjuvant for muscle growth and strength strengthening in the general public as well as for muscle loss caused by aging or disease.

[0066]

[0067] According to another aspect of the present invention, the present invention provides a method for preventing or treating a disease caused by muscle weakness, muscle loss, or muscle atrophy, comprising the step of administering the strain of Lactiplantibacillus plantarum MTY001 (accession number: KCTC15788BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof to an individual in need thereof.

[0068] The above-mentioned strain of Lactiplantibacillus plantarum MTY001 (accession number: KCTC15788BP), its culture medium, its concentrate, its lysate, its dried form, or a combination thereof may be administered to individuals requiring it in a therapeutically effective amount. Preferably, the individuals are mammals, including humans, and include both patients who have received prevention or treatment for diseases caused by muscle loss, muscle atrophy, or muscle atrophy, and patients who need to receive prevention or treatment for diseases caused by muscle loss, muscle atrophy, or muscle atrophy; patients who have undergone other therapies or treatments for the prevention or treatment of diseases caused by muscle loss, muscle atrophy, or muscle atrophy may also be included.

[0069] Furthermore, the present invention may be used in combination with existing drugs or treatment methods for the prevention or treatment of diseases caused by muscle loss, muscle atrophy, or muscle weakness. When the present invention is used in combination, it may be used simultaneously or sequentially with other drugs or treatment methods for the prevention or treatment of diseases caused by muscle loss, muscle weakness, or muscle atrophy.

[0070]

[0071] According to another aspect of the present invention, the present invention provides the use of the Lactiplantibacillus plantarum MTY001 (accession number: KCTC15788BP) strain, its culture medium, its concentrate, its lysate, its dried form, or a combination thereof for the manufacture of a drug for the prevention or treatment of diseases caused by muscle weakness, muscle loss, or muscle atrophy.

[0072]

[0073] Redundant content is omitted out of consideration for the complexity of this specification, and terms not otherwise defined in this specification have the meanings commonly used in the technical field to which this invention belongs.

[0074] The present invention will be described in more detail below through examples. These examples are solely for illustrating the present invention, and it will be obvious to those skilled in the art that the scope of the present invention is not to be interpreted as being limited by these examples.

[0075]

[0076] Example 1. Selection and Characterization of Lactic Acid Bacteria Promoting Muscle Differentiation and Formation

[0077] Lactibacillus plantarum MTY001, which has activity promoting muscle differentiation and formation, was selected from a library of lactic acid bacteria cultures. Mito Therapeutics Co., Ltd. (Rm. 305, Annex Building, Industry-Academic Research and Education Center, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon, Korea) deposited the above Lactibacillus plantarum MTY001 with the Biological Resource Center (Jeongeup-si, Jeollabuk-do, Korea) in accordance with the Treaty of Budapest on August 14, 2024, and was assigned accession number KCTC15788BP.

[0078] 1-1. Genome-based analysis of the MTY001 strain

[0079] The phylogenetic tree and ANI were analyzed based on the whole genome of the MTY001 strain isolated from kimchi and are shown in Figure 1. It was confirmed that the MTY001 strain of the present invention has a 3.27 Gb genome analyzed into 32 contigs and possesses 3,148 genes. These genes include 3,080 CDS, 60 tRNAs, 7 rRNAs, and 1 tmRNA.

[0080]

[0081] 1-2. Antibiotic susceptibility of MTY001 strain

[0082] The antibiotic susceptibility of Lactiplantibacillus plantarum MTY001 was evaluated using minimum inhibitory concentration (MIC) test strips (KisanBio, Korea). The antibiotic susceptibility of the strain to eight antimicrobial agents, including ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, and tetracycline, was tested according to the guidelines of the European Food Safety Authority (EFSA). Specifically, cells were aerobically cultured in MRS medium at 37°C for 18 hours, harvested by centrifugation at 11,000 rpm for 5 minutes, and washed three times with PBS (pH 7.4). The washed cells were resuspended in PBS at McFarland Standard 0.5. The cell suspension was inoculated onto BHI agar containing cotton swabs. The plates were dried for 10–15 minutes, and MIC test strips were placed on the agar surface. Next, after incubating the plates at 37°C for 48 hours, the MIC was read based on the intersection of the MIC scale on the test strip and the elliptical area of ​​growth inhibition. Cutoff values ​​for various antibiotics were evaluated according to EFSA guidelines. The results of evaluating antibiotic resistance using MIC and hemolysis tests are shown in Table 1.

[0083] As a result of antibiotic susceptibility testing, it was confirmed that the bacteria were susceptible to most antibiotics, but showed resistance to ampicillin (AM) and chloramphenicol (CL) and inherent resistance to vancomycin (VM). In particular, it was confirmed that bacterial growth was inhibited at minimum inhibitory concentrations (MIC) for gentamicin (GM), kanamycin (KM), erythromycin (EM), and tetracycline (TC) that were more than half lower than the cut-off value.

[0084] Strain nameStrainAntimicrobial susceptibility (MIC) (μg / mL)AMVMGMKMSMEMCMTCCLCut-off values2n.r.1664n.r.12328L.plantarumMYT0013>0.532320.1251.51612

[0085] *nr not required; Ampicillin (AM); Vancomycin (VM); Gentamicin (GM); Kanamycin (KM); Streptomycin (SM); Erythromycin (EM); Clindamycin (CM); Tetracycline (TC); Chloramphenicol (CL)

[0086]

[0087] 1-3. Muscle differentiation and formation-promoting activity of MTY001 strain

[0088] C2C12 mouse myoblasts 1 x 10 4 Cells were mixed with culture medium (DMEM, 10% FBS, 1% AA), seeded into 96-well plates, and cultured in an incubator for 24 hours. After 24 hours, YY1-promoter-gaussia luciferase DNA (pYY1-Gluc, 50 ng) and Flag-PHF20 DNA (200 ng) were introduced into the cells using Lipofectamine 3000 (cat# L3000001, Invitrogen) according to the manufacturer's manual. 24 hours after introduction, the culture medium was replaced with fresh medium, and 1 x 10⁶ 8CFU of Lactobacillus plantarum MTY001 culture medium (CM) was added to the cell culture medium at a concentration of 0.5-4% and cultured for an additional 24 hours. After the culture was completed, YY1-promoter activity was analyzed by measuring the activity of Gaucia luciferase. The Gaucia luciferase activity was measured using a dedicated reagent (cat#LF062, Genecopenia), and the experiment was performed according to the manufacturer's manual. In addition, the control groups for this experiment were YY1-promoter-Gaucia luciferase without culture medium treatment, and YY1-promoter-Gaucia luciferase+PHF20. As a comparative experimental group, the YY1 promoter activity was compared after treating the culture medium of nine other Lactobacillus plantarum strains distributed by the Korea Research Institute of Biotechnology and Bioengineering in the same manner. The results of the YY1 promoter activity measurement are shown in Figure 2a.

[0089] As shown in Figure 2a, the MTY001 lactic acid bacteria culture inhibited YY1 promoter activation induced by PHF20 (***P<0.001) in a concentration-dependent manner (**P<0.01). In addition, it was confirmed that the MTY001 strain exhibited excellent YY1 promoter inhibitory activity compared to other Lactiplantibacillus plantarum strains, whereas the 9 Lactiplantibacillus plantarum strains used as a comparative group showed no YY1 promoter inhibitory activity at all.

[0090] Accordingly, the Lactibacillus plantarum MTY001 strain of the present invention was selected as a strain having excellent muscle differentiation and formation-promoting activity, and the strain of the present invention and its culture medium were used in additional experiments below.

[0091]

[0092] Example 2. Confirmation of cytotoxicity of lactic acid bacteria culture solution

[0093] To confirm the cytotoxicity of the MTY001 lactic acid bacteria culture medium, an MTT assay (Ez-Cytox, cat#EZ-3000, DoGenBio) was performed on the samples of Examples 1-3 according to the manufacturer's manual, and cell viability was measured. Figure 2b is a graph showing the cell viability measurement results as mean + standard deviation (n=3 / sample).

[0094] As shown in Figure 2b, treatment with MTY001 lactic acid bacteria culture medium inhibited the decrease in cell viability (**P<0.01) caused by the introduction of PHF20 in a culture medium concentration (0.5-4%)-dependent manner (**P<0.01 or ***P<0.001) and maintained cell viability. This indicates that the MTY001 lactic acid bacteria culture medium is non-cytotoxic.

[0095]

[0096] Example 3. Confirmation of the effects of lactic acid bacteria culture on muscle degradation, differentiation, and the expression of synthetic biomarkers

[0097] 3-1. Muscle Atrophy C2C12-Cell Model

[0098] The effects of MTY001 lactic acid bacteria culture medium on the expression of biomarkers for muscle degradation (Atrogin-1, MuRF-1), muscle differentiation (MyoD, myogenin, Myh 7), and muscle synthesis (S6K1, 4EBP1 phosphorylation) in a muscle atrophy C2C12-cell model were investigated. Specifically, C2C12 myoblasts were seeded into 6-well plates and cultured in the medium until the plates were more than 90% full; subsequently, the medium was changed to myotube differentiation medium (DMEM, 2% Horse Serum, 1% AA) to induce myotube differentiation. Differentiation was carried out for 5 days, with the medium being replaced daily. To induce muscle atrophy, dexamethasone (DEX, 100 μM) was administered at day 4, at which point 1 x 10⁶ 8CFU of MTY001 lactic acid bacteria culture medium was treated simultaneously. After 24 hours of dexamethasone treatment, the medium was removed and the cells were harvested after washing once with PBS.

[0099]

[0100] 3-2. Protein Expression Analysis

[0101] The above intracellular protein extraction is performed using a protein extraction solution (PRO-PREP TM Proteins were extracted using Protein Extraction Solution (iNtRON) according to the manufacturer's protocol, and then separated using 12–15% SDS-PAGE. The separated proteins were then transferred to a PVDF membrane, and membrane blocking was performed with 5% skim milk / TBS-T (0.05% Tween-20) at room temperature for 1 hour. Subsequently, Western blotting was performed using the following antibodies: Abcam's Atrogin-1 (#ab92281), Cell Signaling Technology's p-S6K1 (#9205), S6K1 (#9202), p-4EBP1 (#9459), Santa Cruz's MuRF-1 (sc-398608), MyoD (sc-377460), GAPDH (sc-25778), and Sigma Aldrich's β-actin (#A2228). GAPDH and β-actin were used as internal controls to correct for total protein amounts between samples. The results of protein expression analysis are shown in Figures 3a to 3c.

[0102] As shown in Figure 3a, it was confirmed that the expression of the muscle degradation biomarker Atrogin-1, which was increased by dexamethasone treatment, decreased in a manner dependent on the treatment concentration (0.25-1%) of MTY001 lactic acid bacteria culture.

[0103] As shown in Figures 3b and c, treatment with MTY001 lactic acid bacteria culture inhibited the decrease in expression of MyoD, a muscle differentiation marker induced by dexamethasone, the increase in the muscle degradation marker MuRF-1, and the decrease in phosphorylation of the muscle synthesis markers S6K1 and 4EBP1.

[0104]

[0105] 3-3. mRNA Expression Analysis

[0106] RNA isolation, cDNA synthesis, and Q-PCR samples were prepared using the AccuPrep® Universal RNA Extraction Kit, AccuPower® RT PreMix, and AccuPower® 2X GreenStar, respectively. TM qPCR was performed using MasterMix (Bioneer, Korea) according to each manufacturer's protocol. The PCR reaction was carried out using an AriaMx real-time PCR instrument (Agilent) under the following conditions: 1) initial denaturation step, 3 min at 95°C, 2) denaturation step, 15 sec at 95°C, 3) annealing step, 30 sec at 60°C, 4) extension step, 30 sec at 72°C, and steps 2) through 4) were performed for 40 cycles.

[0107] The primer sequences used for PCR are as shown in Table 2.

[0108] Sequence No. Gene Forward Primer (5'-3') 1 mouse GAPDHTCCAGTATGACTCCACTC 2 mouse Atrogin-1AACCGGGAGGCCAGCTAAAGAACA 3 mouse MuRF-1GAGAACCTGGAGAAGCAGCT 4 mouse Myh 7ATGAGCTGGAGGCTGAGCA 5 mouse MyoDCCACTCCGGGACATAGACTTG 6 mouse myogeninGAGACATCCCCCTATTTCTACCA Reverse Primer (5'-3') 7 mouse GAPDHATTTCTCGTGGTTCACAC 8 mouse Atrogin-1TGGGCCTACAGAACAGACAGTGC 9 mouse MuRF-1CCGCGGTTGGTCCAGTAG 10 mouse Myh 7TGCAGCCGCAGTAGGTTCTT 11 mouse MyoDAAAAGCGCAGGTCTGGTGAG 12 mouse myogeninGCTCAGTCCGCTCATAGCC

[0109]

[0110] The mRNA expression level of each gene is 2 after adjusting for the expression level of the internal control gene GAPDH. -ΔΔct Calculated using the method. The results are the mRNA expression analysis results for each gene, and the graphs represent the mean and standard deviation of three replicate experiments per sample. The results of the mRNA expression analysis are shown in Figures 4a and 4b.

[0111] As shown in Figures 4a and 4b, it was confirmed that dexamethasone treatment increased the mRNA expression of muscle degradation markers Atrogin-1 and MuRF-1, and decreased the mRNA expression of muscle differentiation markers MyoD, myogenin, and Myh7. However, these effects caused by dexamethasone were inhibited by treatment with MTY001 lactic acid bacteria culture medium.

[0112]

[0113] Example 4. Confirmation of the myotube formation-promoting effect of MTY001 lactic acid bacteria

[0114] 4-1. Effect of MTY001 Lactic Acid Bacteria Culture Solution on Promoting Myotube Formation

[0115] In this example, the myotube formation-promoting effect of the MTY001 lactic acid bacteria culture solution was confirmed. Specifically, a sterile glass coverslip was placed in a 24-well plate, and 5 x 10 per well 4 C2C12 Cells were seeded and cultured in culture medium for 24 hours. After 24 hours, the culture medium was removed and replaced with differentiation medium to differentiate into myotubes for 5 days. During the differentiation period, 1 x 10⁶ 8 CFU of MTY001 lactic acid bacteria culture was added to the differentiation medium to a concentration of 2%, and the differentiation medium was changed daily. Dexamethasone was administered starting on the third day of differentiation, and cells were harvested on the fifth day. Myotube formation was observed using the myotube biomarker MyHC (myosin heavy chain) immunofluorescence staining. Specifically, the harvested cells were washed twice with PBS and fixed in 4% paraformaldehyde for 15 minutes at room temperature. Then, they were washed three times with PBS and incubated in 0.2% Triton x-100 / PBS for 10 minutes at room temperature, followed by three washes with PBS and blocking the cells in 1% BSA / PBS for 1 hour at room temperature. Subsequently, the anti-MYH antibody (Santacruz, sc-376157) was diluted 1:1000 in 1% BSA and incubated at 4°C for 24 hours. The next day, after washing 3 times with PBS, Alexa Fluor TM Plus 488-second antibody (Invitrogen, Cat # A32723: 1:5000, diluted with PBS) was reacted for 1 hour at room temperature under light-blocked conditions. Fluorescently stained myotube cells were stained for cell nuclei using DAPI VECTASHIELD (St. Louis, USA), and after mounting the coverslips on glass slides, images were taken using a Zeiss fluorescence microscope. The results of the fluorescence staining are shown in Figure 5.

[0116] As shown in Figure 5, the reduction of myotube cells caused by dexamethasone treatment was inhibited by treatment with MTY001 lactic acid bacteria culture.

[0117]

[0118] Example 5. In vivo muscle strength evaluation of MTY001 lactic acid bacteria

[0119] 5-1. Study Schedule for Evaluating Muscle Efficacy of MTY001 Lactobacillus Culture in Aged Mice

[0120] An aged mouse model was used to evaluate the efficacy of MTY001 lactic acid bacteria culture in improving muscle strength and muscle mass. Specifically, 1x10 8 200 µl of CFU of MTY001 lactic acid bacteria culture was orally administered to 60-week-old aged mice for 41 days. The control group was administered PBS. Each group consisted of 6 mice. Body weight was measured periodically during administration, and grip strength was measured before administration and on the 35th day after administration. To measure muscle mass, body composition was analyzed using dual-energy x-ray absorptiometry (DXA) after the administration was completed. Subsequently, the mice were euthanized, and tissue from the gastrocnemius muscle (GA) of the hind legs was isolated.

[0121]

[0122] 5-2. Improvement in Grip Strength Following Administration of MTY001 Lactobacillus Culture in Aged Mice

[0123] Changes in body weight and grip strength evaluation results of aged mice orally administered MTY001 lactic acid bacteria culture are shown in Figures 6a and 6b.

[0124] As shown in Figures 6a and 6b, the group administered MTY001 lactic acid bacteria culture showed improved grip strength compared to before administration without significant change in body weight compared to the control group (P<0.05). On the other hand, the control group showed no significant change in grip strength before and after administration.

[0125]

[0126] 5-3. Study Schedule for Evaluation of Muscle Efficacy of MTY001 Lactobacillus (Live Bacteria) in a Dexamethasone-Induced Muscle Atrophy Mouse Model

[0127] As shown in Fig. 7a, a dexamethasone-induced muscle atrophy mouse model for the administration of MTY001 live probiotics was prepared. Specifically, 7-week-old male C57BL / 6N mice were acclimatized in the rearing room for one week, after which the mice were randomly divided into a Control group, a DEX group, and an MTY001 group (N=5 / group), and muscle atrophy was induced by daily intraperitoneal injection of dexamethasone (20 mg / kg) for 8 days. Subsequently, starting from the 11th day, 1 x 10⁶ suspended in PBS (Control and DEX groups) or 100 µl PBS 8 CFU of MTY001 lactic acid bacteria (live bacteria) (MTY001 group) was orally administered daily for 38 days (until the 48th day of dexamethasone administration). Grip strength was measured on the 11th, 15th, 22nd, and 43rd days of dexamethasone administration, and body weight was measured periodically as shown in Fig. 7a. Body composition was measured via DXA on the 48th day of dexamethasone administration, and on the 49th day, the mice were euthanized and tibialis anterior (TA) muscle tissue of the hind legs was isolated.

[0128]

[0129] 5-4. Improvement in Grip Strength Following Administration of MTY001 Lactobacillus (Live) in a Dexamethasone-Induced Muscle Atrophy Mouse Model

[0130] Changes in body weight and grip strength evaluation results of dexamethasone-induced muscular dystrophy mice administered MTY001 probiotics (live bacteria) are shown in Figures 7b and 7c, respectively.

[0131] As shown in Figure 7b, the group administered dexamethasone (DEX, MTY001 group) showed a significant decrease in body weight compared to the control group on day 20 (**P<0.01). This indicates that a muscle atrophy model induced by dexamethasone has been established. This decrease in body weight was restored to the control group level upon weight measurement on day 27.

[0132] As shown in Figure 7c, when grip strength was measured on day 11, the grip strength of the groups administered dexamethasone (DEX group, MTY001 group) was significantly reduced compared to the control group (***P<0.001). Then, when grip strength was measured on days 22 and 43, the grip strength of the MTY001 group recovered to the level of the control group, but the grip strength of the DEX group was found to be significantly reduced compared to the control group and the MTY001 group. These results indicate that the decrease in grip strength caused by dexamethasone administration is inhibited by the administration of MTY001 lactic acid bacteria (live bacteria).

[0133]

[0134] Example 6. Evaluation of muscle mass following administration of MTY001 lactic acid bacteria

[0135] 6-1. Increase in muscle mass following administration of MTY001 lactic acid bacteria culture

[0136] Total muscle mass was measured using DXA after the oral administration of the MTY001 lactic acid bacteria culture solution for 41 days in the same manner as in Example 5, and the measurements were expressed as the mean and standard error (n=6 / group). The results of the total muscle mass measurement are shown in Fig. 8a.

[0137] As shown in Figure 8a, the total muscle mass of aged mice administered MTY001 lactic acid bacteria culture was significantly increased compared to the control group (PBS administration group) (***P<0.001).

[0138]

[0139] 6-2. Increase in Muscle Mass Following Administration of MTY001 Probiotics (Live Bacteria)

[0140] After the administration of MTY001 lactic acid bacteria (live bacteria) was completed in the same manner as in Example 5, the muscle mass of the right hind leg was measured using DXA. The muscle mass of each group was expressed as the mean and standard error (n=5 / group). The results of measuring the right hind leg muscle mass are shown in Fig. 8b.

[0141] As shown in Figure 8b, the DEX group showed a decrease in muscle mass compared to the control group (*P<0.05). On the other hand, the MTY001 group significantly inhibited the decrease in muscle mass caused by dexamethasone administration (**P<0.01).

[0142]

[0143] Example 7. Evaluation of changes in muscle differentiation, degradation, and synthesis biomarkers following administration of MTY001 lactic acid bacteria

[0144] 7-1. Changes in Muscle Biomarker Expression Following Administration of MTY001 Lactic Acid Bacteria Culture

[0145] Protein expression of muscle degradation and synthetic biomarkers in gastrocnemius muscle tissue of aged mice administered MTY001 lactic acid bacteria culture in the same manner as in Example 5 was measured by Western blotting. Protein expression measurements were performed using the method of Example 2-2, and for Western blotting of p-AKT and AKT, Cell Signaling Technology's p-AKT (#4060) and AKT (#9272) antibodies were used. The Western blotting antibodies for other markers were the same as those used in Example 2-2. The Western blotting results are shown in Fig. 9a, and the graphs of each protein expression level quantified using Image J software are shown in Fig. 9b (mean + standard error, n=6 / group).

[0146] As shown in Figures 9a and 9b, the expression of phosphorylated proteins of AKT and 4EBP1, which are muscle synthesis markers, was significantly increased in the group administered MTY001 lactic acid bacteria culture compared to the control group (*P<0.05 and **P<0.01, respectively). On the other hand, the expression of Atrogin-1, a muscle degradation marker, was significantly decreased in the group administered MTY001 lactic acid bacteria culture compared to the control group (***P<0.001). These results indicate that MTY001 lactic acid bacteria culture is effective in promoting muscle synthesis and inhibiting muscle degradation in aged mice.

[0147]

[0148] 7-2. Changes in Muscle Biomarker Expression Following Administration of MTY001 Lactic Acid Bacteria (Live Bacteria)

[0149] mRNA expression of muscle differentiation, degradation, and synthesis markers in anterior tibial muscle tissue of dexamethasone-induced muscle atrophy mice administered MTY001 lactic acid bacteria (live bacteria) in the same manner as in Example 5 was analyzed by Q-PCR. mRNA analysis was performed using the method of Examples 2-3 above. The results of the analysis of mRNA expression of muscle differentiation, degradation, and synthesis markers are shown in Figure 10.

[0150] As shown in Figure 10, compared to the control group, the expression of muscle differentiation (Myh 7, myogenin) and muscle synthesis (S6K1) markers decreased, while the expression of the muscle degradation marker MuRF-1 increased. These changes caused by dexamethasone administration were significantly inhibited by the administration of MTY001 lactic acid bacteria (live bacteria).

[0151]

[0152] Example 8. Statistical Analysis

[0153] Differences between samples were statistically analyzed using Excel's paired t-test or unpaired t-test, with *; P-value (reliability) <0.05, **; p<0.01, ***; p<0.001. P<0.05 was interpreted as a statistically significant difference. Cases where there was no statistically significant difference were indicated as ns.

[0154]

[0155] In summary, the inventors selected a strain of the genus Lactiplantibacillus that promotes muscle differentiation and formation. Furthermore, experiments confirmed that the selected strain of the genus Lactiplantibacillus not only has no cytotoxicity but also inhibits muscle degradation while simultaneously promoting muscle synthesis. Therefore, the strain of the genus Lactiplantibacillus of the present invention can be utilized in various fields related to the treatment of muscle loss diseases and muscle growth.

[0156]

[0157] Foregoing, specific parts of the present invention have been described in detail. It will be apparent to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.

[0158] Deposit of biological materials

[0159] Lactibacillus plantarum MTY001 was deposited with the Biological Resource Center (Jeongeup-si, Jeollabuk-do, Korea) on August 14, 2024, in accordance with the Treaty of Budapest, and was assigned accession number KCTC15788BP.

[0160] If the patent is granted, all restrictions on the public use of the deposited culture are irrevocably lifted, and the applicant retains the right to request that a request for the deposit be made in accordance with 37 CFR §1.808(b).

[0161] The deposit will be kept for 30 years from the date of deposit or 5 years from the date of the last sample request or for the longer of the patent term, and will be maintained with all necessary care to keep it viable and uncontaminated in any case.

[0162] The applicant requests that, for all designated and / or elected countries, and to the extent legally permissible under the laws of such countries, the samples of biological material deposited in this application be made available only to independent experts in accordance with applicable patent laws, e.g., Rule 32 of the European Patent Convention (EPC), Rule 13(1) and Sections 6 and 7 of the UK Patent Rule 2007 (Revised), and similar provisions applicable to other designated countries.

[0163] On February 13, 2025, the applicant succeeded to the right to reference and use the strain with accession number KCTC15788BP in the present invention from Mitotherapeutics Co., Ltd., and prepared a declaration to that effect on April 14, 2026, and submitted it together with the PCT application.

[0164]

Claims

1. A food composition for the prevention or improvement of muscle strength and muscle loss; or muscle atrophy comprising the strain Lactiplantibacillus plantarum MTY001 (Accession No.: KCTC15788BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.

2. The strain of claim 1 is a composition having one or more activities selected from the group consisting of promoting differentiation of muscle cells, inhibiting apoptosis of muscle cells, improving muscle strength, improving exercise performance, and increasing mineral content in the body.

3. A food composition according to claim 1, wherein the prevention or improvement of muscle strength and muscle reduction; or muscle atrophy is muscle strengthening, muscle strength improvement, muscle augmentation, promotion of muscle differentiation, or muscle regeneration.

4. A health functional food composition for the prevention or improvement of muscle strength and muscle loss; or muscle atrophy, comprising the strain Lactiplantibacillus plantarum MTY001 (Accession No.: KCTC15788BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.

5. A pharmaceutical composition for the prevention or treatment of diseases caused by muscle strength and muscle loss; or muscle atrophy, comprising the strain Lactiplantibacillus plantarum MTY001 (Accession No.: KCTC15788BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.

6. A composition according to claim 5, wherein the muscle strength and muscle loss; or the disease resulting from muscle atrophy is one or more selected from the group consisting of sarcopenia, atony, muscular atrophy, muscular dystrophy, muscle degeneration, myotonic dystrophy, amyotrophic lateral sclerosis, myasthenia, and cachexia.

7. A feed composition for the prevention or improvement of muscle strength and muscle loss; or muscle atrophy comprising the strain Lactiplantibacillus plantarum MTY001 (Accession No.: KCTC15788BP), its culture medium, its concentrate, its lysate, its dried form, or a combination thereof.

8. A composition for strengthening muscle and increasing muscle mass comprising the strain Lactiplantibacillus plantarum MTY001 (Accession No.: KCTC15788BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.

9. A method for preventing or treating muscle strength and muscle loss; or diseases caused by muscle atrophy, comprising the step of administering the strain of Lactiplantibacillus plantarum MTY001 (accession number: KCTC15788BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof to an individual in need thereof.

10. Use of the strain Lactiplantibacillus plantarum MTY001 (Accession No.: KCTC15788BP), its culture medium, its concentrate, its lysate, its dried form, or a combination thereof, for the manufacture of a drug for the prevention or treatment of diseases caused by muscle weakness and muscle loss; or muscle atrophy.